Cancer CXC chemokine networks and tumour angiogenesis

European Journal of Cancer

Volumn 42, Issue 6, 2006, Pages 768-778

  Strieter, Robert M ^a   Burdick, Marie D ^a   Mestas, Javier ^a   Gomperts, Brigitte ^a   Keane, Michael P ^a   Belperio, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Angiostasis; Cancer; CXC chemokines; Tumourigenesis

Indexed keywords

ALPHA CHEMOKINE; ANGIOSTATIC PROTEIN; ARGININE; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMIC ACID; INTERFERON; LEUCINE; THROMBOCYTE FACTOR 4;

ANGIOGENESIS; ARTICLE; CANCER; CARCINOGENESIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; ENDOTHELIUM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REGULATORY MECHANISM; TH1 CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATIC PROTEINS; CHEMOKINES, CXC; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33646472556     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.006     Document Type: Article

References (101)

1. Auerbach W., and Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 63 3 (1994) 265-311
2. Auerbach R., Auerbach W., and Polakowski I. Assays for angiogenesis: a review. Pharmacol Ther 51 1 (1991) 1-11
3. Ziche M., Morbidelli L., and Donnini S. Angiogenesis. Exp Nephrol 4 (1996) 1-14
4. Pluda J.M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24 2 (1997) 203-218
5. Pluda J.M., and Parkinson D.R. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 78 suppl 3 (1996) 680-687
6. Gastl G., Hermann T., Steurer M., et al. Angiogenesis as a target for tumor treatment. Oncology 54 3 (1997) 177-184
7. Risau W. Angiogenesis is coming of age [Editorial; Comment]. Circ Res 82 8 (1998) 926-928
8. Risau W. Mechanisms of angiogenesis. Nature 386 6626 (1997) 671-674
9. Hotfilder M., Nowak-Gottl U., and Wolff J.E. Tumorangiogenesis: a network of cytokines. Klin Padiatr 209 4 (1997) 265-270
10. Hui Y.F., and Ignoffo R.J. Angiogenesis inhibitors. A promising role in cancer therapy. Cancer Pract 6 1 (1998) 60-62
11. Kumar R., and Fidler I.J. Angiogenic molecules and cancer metastasis. In Vivo 12 1 (1998) 27-34
12. Zetter B.R. Angiogenesis. State of the art. Chest 93 suppl 3 (1988) 159S-166S
13. Zetter B.R. Angiogenesis and tumor metastasis. Annu Rev Med 49 (1998) 407-424
14. Lund E.L., Spang-Thomsen M., Skovgaard-Poulsen H., and Kristjansen P.E. Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol Scand 97 1 (1998) 52-62
15. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 7 (1998) 436-445
16. Belperio J.A., Keane M.P., Arenberg D.A., et al. CXC chemokines in angiogenesis. J Leukoc Biol 68 1 (2000) 1-8
17. Strieter R.M., Polverini P.J., Kunkel S.L., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270 45 (1995) 27348-27357
18. Nor J.E., Christensen J., Liu J., et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61 5 (2001) 2183-2188
19. Heidemann J., Ogawa H., Dwinell M.B., et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278 10 (2003) 8508-8515
20. Schruefer R., Lutze N., Schymeinsky J., and Walzog B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol (2004)
21. Dong G., Chen Z., Li Z.Y., Yeh N.T., Bancroft C.C., and Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61 15 (2001) 5911-5918
22. Hirata A., Ogawa S., Kometani T., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62 9 (2002) 2554-2560
23. Levine L., Lucci III J.A., Pazdrak B., et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 63 13 (2003) 3495-3502
24. Richmond A., and NF-kappa B. chemokine gene transcription and tumour growth. Nat Rev Immunol 2 9 (2002) 664-674
25. Addison C.L., Daniel T.O., Burdick M.D., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR(+) CXC chemokine-induced angiogenic activity. J Immunol 165 9 (2000) 5269-5277
26. Murdoch C., Monk P.N., and Finn A. CXC chemokine receptor expression on human endothelial cells. Cytokine 11 9 (1999) 704-712
27. Sugden P.H., and Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G protein- coupled receptors. Cell Signal 9 5 (1997) 337-351
28. Pawson T., and Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science 278 5346 (1997) 2075-2080
29. Shyamala V., and Khoja H. Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry 37 45 (1998) 15918-15924
30. Couty J.P., and Gershengorn M.C. Insights into the viral G protein-coupled receptor encoded by human herpesvirus type 8 (HHV-8. Biol Cell 96 5 (2004) 349-354
31. Manna S.K., and Ramesh G.T. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. J Biol Chem 280 8 (2005) 7010-7021
32. Keane M.P., Belperio J.A., Xue Y.Y., Burdick M.D., and Strieter R.M. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172 5 (2004) 2853-2860
33. Addison C.L., Belperio J.A., Burdick M.D., and Strieter R.M. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4 1 (2004) 28
34. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., and Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97 12 (1996) 2792-2802
35. Arenberg D.A., Keane M.P., DiGiovine B., et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 102 3 (1998) 465-472
36. Moore B.B., Arenberg D.A., Stoy K., et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154 5 (1999) 1503-1512
37. Strieter R.M., Belperio J.A., Arenberg D.A., Smith M.I., Burdick M.D., and Keane M.P. CXC chemokine in angiogenesis. In: Ransohoff R., Suzuki K., Proudfoot A., and Hickey W. (Eds). Universes in delicate balance: chemokines and the nervous system (2002), Elsevier Science BV, Amsterdam, The Netherlands 129-148
38. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16 (1998) 225-260
39. Pold M., Zhu L.X., Sharma S., et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 64 5 (2004) 1853-1860
40. American Cancer Society. Cancer Facts and Figures 2004: Selected Cancers. American Cancer Society, 2004.
41. Garkavtsev I., Kozin S.V., Chernova O., et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428 6980 (2004) 328-332
42. Wu J.L., Abe T., Inoue R., Fujiki M., and Kobayashi H. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 26 7 (2004) 785-791
43. Xiong H.Q., Abbruzzese J.L., Lin E., Wang L., Zheng L., and Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 108 2 (2004) 181-188
44. Sparmann A., and Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 5 (2004) 447-458
45. Luan J., Shattuck-Brandt R., Haghnegahdar H., et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 62 5 (1997) 588-597
46. Owen J.D., Strieter R., Burdick M., et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int J Cancer 73 1 (1997) 94-103
47. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., and Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90 6 (1998) 447-454
48. Gawrychowski K., Skopinska-Rozewska E., Barcz E., et al. Angiogenic activity and interleukin-8 content of human ovarian cancer ascites. Eur J Gynaecol Oncol 19 3 (1998) 262-264
49. Smith D.R., Polverini P.J., et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179 5 (1994) 1409-1415
50. Arenberg D.A., Kunkel S.L., Burdick M.D., Polverini P.J., and Strieter R.M. Treatment with anti-IL-8 inhibits non-small cell lung cancer tumor growth. J Investig Med 43 suppl 3 (1995) 479A
51. Yatsunami J., Tsuruta N., Ogata K., et al. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer Lett 120 1 (1997) 101-108
52. White E.S., Flaherty K.R., Carskadon S., et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9 2 (2003) 853-860
53. Chen J.J., Yao P.L., Yuan A., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9 2 (2003) 729-737
54. Bostwick D.G., and Iczkowski K.A. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 16 3 (1998) 118-123
55. Fregene T.A., Khanuja P.S., Noto A.C., et al. Tumor-associated angiogenesis in prostate cancer. Anticancer Res 13 6B (1993) 2377-2381
56. Kim S.J., Uehara H., Karashima T., McCarty M., Shih N., and Fidler I.J. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3 1 (2001) 33-42
57. Miller L.J., Kurtzman S.H., Wang Y., Anderson K.H., Lindquist R.R., and Kreutzer D.L. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 18 1A (1998) 77-81
58. Richards B.L., Eisma R.J., Spiro J.D., Lindquist R.L., and Kreutzer D.L. Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg 174 5 (1997) 507-512
59. Kitadai Y., Haruma K., Sumii K., et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 152 1 (1998) 93-100
60. Singh R.K., Gutman M., Radinsky R., Bucana C.D., and Fidler I.J. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54 12 (1994) 3242-3247
61. Cohen R.F., Contrino J., Spiro J.D., Mann E.A., Chen L.L., and Kreutzer D.L. Interleukin-8 expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 121 2 (1995) 202-209
62. Chen Z., Malhotra P.S., Thomas G.R., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5 6 (1999) 1369-1379
63. Shellenberger T.D., Wang M., Gujrati M., et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and is a chemotactic factor for immature dendritic cells. Cancer Res 64 (2004) 8262-8270
64. Struyf S., Burdick M.D., Proost P., Van Damme J., and Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 95 9 (2004) 855-857
65. Maione T.E., Gray G.S., Petro J., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247 4938 (1990) 77-79
66. Rollins B.J. Chemokines. Blood 90 3 (1997) 909-928
67. Balkwill F. The molecular and cellular biology of the chemokines. J Viral Hepat 5 1 (1998) 1-14
68. Strieter R.M., Belperio J.A., Phillips R.J., and Keane M.P. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14 3 (2004) 195-200
69. Strieter R.M., Belperio J.A., Phillips R.J., and Keane M.P. Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp 256 (2004) 173-184 discussion 184-188, 259-269
70. Sharma S., Yang S.C., Hillinger S., et al. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2 1 (2003) 22
71. Hillinger S., Yang S.C., Zhu L., et al. EBV-induced molecule1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 171 12 (2003) 6457-6465
72. Frederick M.J., Henderson Y., Xu X., et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156 6 (2000) 1937-1950
73. Schwarze S.R., Luo J., Isaacs W.B., and Jarrard D.F. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 13 (2005) 13
74. Bachelder R.E., Wendt M.A., and Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62 24 (2002) 7203-7206
75. Salcedo R., and Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10 3-4 (2003) 359-370
76. Kijowski J., Baj-Krzyworzeka M., Majka M., et al. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 19 5 (2001) 453-466
77. Salcedo R., Wasserman K., Young H.A., et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154 4 (1999) 1125-1135
78. Schrader A.J., Lechner O., Templin M., et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86 8 (2002) 1250-1256
79. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001) 50-56
80. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., and Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167 12 (2003) 1676-1686
81. Loetscher M., Loetscher P., Brass N., Meese E., and Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28 11 (1998) 3696-3705
82. Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., and Strieter R.M. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 173 10 (2004) 6234-6240
83. Moser B., and Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2 2 (2001) 123-128
84. Loetscher M., Gerber B., Loetscher P., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184 3 (1996) 963-969
85. Rabin R.L., Park M.K., Liao F., Swofford R., Stephany D., and Farber J.M. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 162 7 (1999) 3840-3850
86. Qin S., Rottman J.B., Myers P., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101 4 (1998) 746-754
87. Beider K., Nagler A., Wald O., et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102 6 (2003) 1951-1958
88. Soto H., Wang W., Strieter R.M., et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 95 14 (1998) 8205-8210
89. Romagnani P., Annunziato F., Lasagni L., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107 1 (2001) 53-63
90. Salcedo R., Resau J.H., Halverson D., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 14 13 (2000) 2055-2064
91. Lasagni L., Francalanci M., Annunziato F., et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197 11 (2003) 1537-1549
92. Yang J., and Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 9 6 (2004) 846-855
93. Burdick M.D., Murray L.A., Keane M.P., et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 171 3 (2005) 261-268
94. Arenberg D.A., Kunkel S.L., Polverini P.J., et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184 3 (1996) 981-992
95. Minna J.D. Neoplasms if the lung. In: Isselbacher K.J. (Ed). Principles of internal medicine. 12th ed. (1991), McGraw-Hill, New York 1102-1110
96. Carney D.N. Cancers of the lungs. In: Carney Fishman A.P. (Ed). Pulmonary diseases and disorders. 2nd ed. (1988), McGraw-Hill, New York 1885-2068
97. Yuan A., Pan-Chyr Y., Chong-Jen Y., et al. Tumor angiogenesis correlates with histologic type and metastasis in non-small cell lung cancer. Am J Resp Crit Care Med 152 (1995) 2157-2162
98. Feldman A.L., Friedl J., Lans T.E., et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 99 1 (2002) 149-153
99. Addison C.L., Arenberg D.A., Morris S.B., et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 11 2 (2000) 247-261
100. Sharma S., Stolina M., Luo J., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164 9 (2000) 4558-4563
101. Tannenbaum C.S., Tubbs R., Armstrong D., Finke J.H., Bukowski R.M., and Hamilton T.A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161 2 (1998) 927-932